Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 2

CLOVER-WaM

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

  • NCT02952508 ↗
  • Active not recruiting
  • Cellectar Biosciences, Inc.
  • 6 commentary sources found
  • Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.

ChannelFound
YouTube2
Podcasts2
X threads2

The trial

ClinicalTrials.gov
Official title
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Phase
Phase 2
Status
Active not recruiting
Conditions
Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma
Interventions
Iopofosine I 131 single dose; Iopofosine I 131 multiple dose; Iopofosine I 131 fractionated dose
Arms
  • Iopofosine I 131, intravenous administration WM · Experimental
  • Iopofosine I 131, intravenous administration MM · Experimental
  • Iopofosine I 131, intravenous administration CNS Lymphoma · Experimental
  • Iopofosine I 131 intravenous administration NHL [CLOSED] · Experimental
Enrollment
120 (estimated)
Primary outcomes
  • Part A [CLOVER-1] Clinical benefit rate
  • Part B [CLOVER-WaM] Major Response Rate
Sponsor
Cellectar Biosciences, Inc.
Start
Jul 26, 2017
Primary completion
Jun 22, 2026 (estimated)
Results posted
No
Registry record
NCT02952508 · updated Mar 18, 2026